Uses
WYE-687 is an ATP-competitive and selective inhibitor of mammalian target of rapamycin (mTOR). Studies have shown the combination of Ras-Raf-MEK1/2 inhibitors with WYE-687 may overcome resistance to mTorKIs thus may be an effective additive therapy for treatment of patient with renal cell carcinoma or colorectal cancer.
Biological Activity
wye-687 is an atp-competitive inhibitor of mtor with ic50 value of 7nm [1].wye-687 is a small-molecule pyrazolopyrimidine inhibitor of mtor1 and mtor2. in the immune-complex kinase assay using his6-akt and his6-s6k as the specific substrates of mtor1 and mtor2, wye-687 prevents mtor from phosphorylating the substrates dose-dependently. besides that, wye-687 is found to highly selective against pi3kα (>100-fold) and pi3kγ (>500-fold) as well as 24 other protein kinases. it is found that wye-687 can suppress cell growth via causing a strong g1 arrest in cell cycle in tumor cell lines including mda361 and hct116. wye-687 also affects the angiogenic factor of cancer cells. it reduces the expression of hif-1α in u87mg, mda361 and lncap cells [1].
in vivo
U937 cells are inoculated into the flanks of SCID/beige mice. When xenografted tumors reach a volume around 100 mm3, mice are orally administrated with either vehicle control (5% ethanol, 2% Tween 80, and 5% polyethylene glycol-400) or WYE-687 (5 or 25 mg/kg) daily for a total of 7 days. The WYE-687 regimen utilized in this study is based on preexperimental results and related studies. WYE-687 administration (5 or 25 mg/kg, daily) significantly inhibits U937 xenograft tumor growth in SCID mice, and the in vivo activity by WYE-687 is dose-dependent. At day 15, the 5 mg/kg WYE-687-treated tumors and 25 mg/kg WYE-687-treated tumors are 50% and 75% smaller than the vehicle control tumors, respectively. Tumor weights of WYE-687-treated mice are also significantly lower than that of vehicle group. Oral administration of WYE-687 potently inhibits U937 leukemic xenograft tumor growth in SCID mice, without causing significant toxicities[2].
IC 50
mTOR: 7 nM (IC
50); mTORC1; mTORC2; PI3K alpha: 81 nM (IC
50); PI3K gamma: 3.11 μM (IC
50); CK1 gamma1: 17.8 μM (IC
50); p38 alpha: 28.9 μM (IC
50)
References
[1] yu k, toral-barza l, shi c, et al. biochemical, cellular, and in vivo activity of novel atp-competitive and selective inhibitors of the mammalian target of rapamycin. cancer research, 2009, 69(15): 6232-6240.
